© Copyright 2015 Galapagos NV Poster available online at: www.glpg.com Defects in CFTR that result in Cystic Fibrosis can be broadly categorized into three.

Slides:



Advertisements
Similar presentations
(DNA-based) cell targeting. Overview Goals 3 designs Possible Implementation Future directions.
Advertisements

Co-Transporters Na + /Glucose Symport Vibrio cholerae Prokaryote Water-bourne pathogen Produces Cholera Toxin.
Discussion Our current results suggest that it is possible to identify susceptibility regions using this methodology. The presented method takes advantage.
Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.
Molecular Basis for Relationship between Genotype and Phenotype DNA RNA protein genotype function organism phenotype DNA sequence amino acid sequence transcription.
Determining the Efficacy of the KillerRed/IL-13.E11Y Fusion Protein: A Cytotoxic, Photo-activated Protein Designed to Target Glioblastomas Fusion E. ColiKR.
Permeability Of Lipid Bilayer Smaller and more hydrophobic molecules diffuse across membrane more rapidly.
Ribosomal Dysfunction Results in an Immunologic Susceptibility to Lung Cancer Stephanie Chang MD, Ryuji Higashikubo PhD, Saeed Arefanian MD, Andrew Gelman.
METHODS Introduction Conclusions  The novel potentiator GP-2 is highly efficacious towards enhancing CFTR function following translational RT of PTCs,
P1586 THE FIRST JAK1-SELECTIVE INHIBITOR, FILGOTINIB, DISPLAYS SIMILAR MOLECULAR ACTIVITY IN THE GUT OF MICE WITH DSS-INDUCED COLITIS AND IN CULTURES OF.
Using additivity and bliss analysis to categorize corrector-corrector interactions Tim Vortherms*, Anne-Sophie Wesse, Arlene Manelli*, Andrew Swensen*,
© Copyright 2015 Galapagos NV Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG1837 in healthy volunteers F.P. Vanhoutte 1, M-H.
Cystic Fibrosis and Gastric Acid Transport March 11, 2008 CH353 Group Project Sidani et al. 2007, DeltaF508 mutation results in impaired gastric acid secretion,
POTENTIATORS: HOW DO THEY IMPACT THE FATE OF CFTR DURING BIOGENESIS? 1 Cellular Protein Chemistry, Faculty of Science, Utrecht University, Padualaan 8,
SC430 Molecular Cell Biology Welcome to Unit 6 Seminar with Dr Hall-Pogar Tonight we will discuss –Biological processes in the cell –Diseases that result.
Date of download: 6/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparison of Cystic Fibrosis Transmembrane Conductance.
Planar Cell Polarity protein network, which controls ciliogenesis and cilia function, is altered in human Cystic Fibrosis Bronchial Epithelial cells through.
Page 1 Protein Labeling — Creative BioMart. Page 2 Our custom protein labeling & conjugation service provides personalized solutions designed to supply.
Novel Transcription Factor Inhibitor as Treatment for Epithelial Cell Cancers John Bushweller, Department of Molecular Physiology and Biological Physics,
RNAi Overview
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
6.3 – Manipulating genomes
Proteolysis Targeting Chimera Profacgen. In mammalian cells, protein degradation is mainly carried out by the ubiquitin- proteasome system to dispose.
LECT 21: REGULATED PROTEIN TURNOVER
Advances in Cystic Fibrosis 2017
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair  Claudia Bilodeau, Olivier Bardou, Émilie Maillé, Yves.
Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel  Emanuela Pesce, Giulia Gorrieri,
Entry Task: Educated Guess!
Volume 19, Issue 10, Pages (October 2012)
Cystic Fibrosis Patients Benefit from Mini Guts
Research Techniques Made Simple: Emerging Methods to Elucidate Protein Interactions through Spatial Proximity  Yonglu Che, Paul A. Khavari  Journal of.
Evaluating Effects of CFTR Modulation in Cystic Fibrosis
Effect of VX-770 (Ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells  Laura Vachel, Caroline Norez, Frédéric.
Z. Kopeikin, Z. Yuksek, H.-Y. Yang, S.G. Bompadre 
The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions  Anne Vankeerberghen, Harry Cuppens, Jean-Jacques.
Volume 142, Issue 2, Pages (February 2012)
Rescue of misfolded recoded cystic fibrosis transmembrane conductance regulator (CFTR) channels. a) Representative Western blot obtained from HEK293 cells.
Cystic Fibrosis: How do CFTR mutations cause cystic fibrosis?
Journal of Cystic Fibrosis
Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation  Venkateshwar Mutyam,
Volume 137, Issue 3, Pages (September 2009)
Targeting ion channels in cystic fibrosis
Volume 21, Issue 5, Pages (May 2014)
Cystic Fibrosis Patients Benefit from Mini Guts
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy
Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking  Graeme W. Carlile, Renaud Robert, Julie Goepp, Elizabeth Matthes,
Facilitated Diffusion is...
Masaoki Kawasumi, Paul Nghiem  Journal of Investigative Dermatology 
Johanna F. Dekkers, Peter Van Mourik, Annelotte M
Andrew K Finn, Jennifer L Whistler  Neuron 
Volume 14, Issue 1, Pages (July 2006)
Function, pharmacological correction and maturation of new Indian CFTR gene mutations  Himanshu Sharma, Mathilde Jollivet Souchet, Isabelle Callebaut,
Addressing Treatment Challenges in Cystic Fibrosis
Poster available online at:
Volume 16, Issue 4, Pages (April 2009)
Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators 
Shaoyan Zhang, Neel K. Ranganath, Daniel Skinner, David M
Volume 3, Issue 1, Pages (January 2013)
Galapagos potentiator and correctors
R. Dekkers, L. A. W. Vijftigschild, A. M. Vonk, E. Kruisselbrink, K. M
Volume 18, Issue 2, Pages (February 2011)
Facilitated Diffusion
Volume 57, Issue 3, Pages (March 2000)
Effect of 14 hit compounds on SMN protein expression in type I SMA patient fibroblast cells (GM03813). Effect of 14 hit compounds on SMN protein expression.
Mutations in the CFTR gene that lead to defective Cl– and other ion transport through CFTR protein channels are the underlying defect of CF CFTR gene mutations.
Novel pharmacological strategies to treat cystic fibrosis
Epstein–Barr Virus Coopts Lipid Rafts to Block the Signaling and Antigen Transport Functions of the BCR  Michelle L Dykstra, Richard Longnecker, Susan.
Presentation transcript:

© Copyright 2015 Galapagos NV Poster available online at: Defects in CFTR that result in Cystic Fibrosis can be broadly categorized into three processes: translational, folding/maturation, and functional. To address the underlying causes affecting the folding/maturation and functional properties of CFTR, two biomolecular activities are required, namely correctors to increase CFTR levels at the cell surface, and potentiators to allow the effective opening of the CFTR channel. Combined, these activities allow chloride ion transport yielding improved hydration of the lung surface and subsequent restoration of mucociliary clearance. Previously, we reported the discovery of new corrector molecules via a HTS screen on CFBe41o- cells harboring HRP-tagged F508del CFTR and on U2OS cells expressing ProLink-tagged F508del CFTR. The corrector compounds exhibited good improvement of channel activity in primary cells derived from F508del CFTR homozygous patients as measured by trans-epithelial clamp circuit (TECC). Kinetic studies of Compound B in the CFBe41o- cells harboring HRP-tagged F508del CFTR 1 demonstrated a difference in the correction rates compared to C18, suggesting that both compounds function by a distinct mechanism(s). Additional kinetic studies using the same compounds and cell system but using Brefeldin to block addition of newly synthesized F508del CFTR at the plasma membrane, showed differences in F508del CFTR levels. Compounds C18 and B prolong the membrane residence time of corrected F580del CFTR. Combination of these compounds further improved stabilization of F508del CFTR at the cell-surface. Stable cell lines containing AVI-tagged CFTR (WT and F508del) in CFBe41o- cells were generated to look at cell surface expression of CFTR, allowing for following the faith of CFTR in cells. Insight into the mechanisms of correctors and potentiators Sara Musch, Corina Balut*, Ann Vandevelde, Tim Vortherms*, Luc Nelles, Chris Tse*, Katja Conrath Galapagos NV, Generaal De Wittelaan L11A3, 2800 Mechelen, Belgium. * AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, US. # Cellular Protein Chemistry, Faculty of Science, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands Conclusions  Various assays were used for better understanding of previously identified novel mechanism correctors. Time needed for correction as well as residence time of corrected F508del CFTR are influenced. A novel cellular assay using AVI-tagged F508del CFTR was developed to visualize by in vivo biotinylation the surface rescued F508del CFTR. This assay can be used for quantification of rescued CFTR levels as well as looking into recycling and trafficking of F508del CFTR, influenced by correctors  Studies using F508del/F508del organoids showed functional rescue of F508del CFTR using correctors and GLPG1837 as potentiator NACFC Poster #70 CFTR F508del – HRP in CFBe41o- G. Lukacs Residence time of HRP-F508del CFTR Correction of HRP-F508del CFTR in time Acknowledgements We would like to thank Dr. Gergely Lukacs for providing the CFBe41o- cells. We would also thank the Cystic Fibrosis Foundation for providing C18. We would like to thank Anabela Ramalho and Kris De Boeck for providing the F508del/F508del organoids. References 1.Phuan, P-W, et.al. (2014) Synergy-Based Small-Molecule Screen Using a Human Lung Epithelial Cell Line Yields DF508-CFTR Correctors That Augment VX-809 Maximal Efficacy. Mol Pharmacol 86:42–51. Summary In summary, these studies have elucidated additional understanding of the interplay between correctors/potentiators and CFTR. We gained more insight on how our corrector molecules do work using several assays to evaluate the impact of corrector/potentiator combinations on the rescue of F508del CFTR, and to understand the contribution of each component in combination cocktails. AVI-tag was inserted in ECL of CFTR allowing for enzymatic conjugation of a single biotin on the tagged target, using the biotin ligase (BirA) from E. coli Degradation rate can be followed by binding fluorescently-tagged streptavidin at cell surface and following the loss of signal Western blot, CFTR-F508del-AVI Total protein Immunofluorescence, Cell surface CFTR-F508del-AVI Internalization Rescue of F508del/F508del CFTR in organoids Organoids from a F508del/F508del patient were prepared and treated with a combination of two correctors for 24 hours. Organoid swelling was followed in time after stimulation with forskolin and GLPG1837. Cmpd C (3µM) AVI-CFTR F508del in CFBe41o-